Benzinga | May 18, 2021 07:01AM EDT

Goldman Sachs Initiates Coverage On Rain Therapeutics with Buy Rating, Announces Price Target of $56

Goldman Sachs analyst Graig Suvannavejh initiates coverage on Rain Therapeutics (NASDAQ:RAIN) with a Buy rating and announces Price Target of $56.